Rohit Jain

Also affiliated with Gujarat Cancer Society

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer”.

Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer

Cancer Chemotherapy and Pharmacology(2025)10.1007/s00280-025-04840-2

N/A

0.241DataRank · unranked

4 citations

Anmbreen Jamroze, Dharmesh Gopalakrishnan, Rohit Jain, Changchuan Jiang, Julianne L. Holleran +11 more

Editorial: Neutrophil Communication

Frontiers in Immunology(2020)10.3389/fimmu.2020.00871

N/A

0DataRank · unranked

2 citations

Rohit Jain, Marco A. Cassatella, Christian Lood, Jason S. Knight

The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures

Frontiers in Immunology(2021)10.3389/fimmu.2021.694079

N/A

0DataRank · unranked

39 citations

Anders Berglund, Logan Zemp, Jasreman Dhillon, Ryan M. Putney, Young‐Chul Kim +5 more

FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma

BJUI Compass(2021)10.1002/bco2.125

N/A

0DataRank · unranked

15 citations

Talal El Zarif, Rohit Jain, William Paul Skelton, Dory Freeman, Catherine Curran +8 more

Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR2/3 genetic alterations (GAs).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps595

N/A

0DataRank · unranked

12 citations

Youngchul Kim, Jennifer Rembisz, Richard Piekarz, Timothy W. Synold, Jingsong Zhang +2 more

Preliminary results from phase Ib/II neoadjuvant CG0070 and nivolumab (N) for cisplatin (C)-ineligible muscle invasive bladder cancer (MIBC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4574

N/A

0DataRank · unranked

3 citations

Philippe E. Spiess, Wade J. Sexton, Scott M. Gilbert, Michael Poch, Julio M. Pow‐Sang +11 more

Inherited Germline Variants in Urinary Tract Cancer: A Multicenter Whole-Exome Sequencing Analysis and Correlation With Clinical Features and Tumor Genomics

JCO Precision Oncology(2024)10.1200/po.23.00697

N/A

0DataRank · unranked

4 citations

David A. Nix, Kristen Pauley, Samantha Greenberg, Aaron Atkinson, Kenneth M. Boucher +16 more

Phase Ib Study of Enzalutamide with Venetoclax in Patients with Metastatic Castration-Resistant Prostate Cancer

medRxiv(2025)10.1101/2025.04.22.25326208

N/A

0DataRank · unranked

1 citations

Anmbreen Jamroze, Dharmesh Gopalakrishnan, Rohit Jain, Changchuan Jiang, Julianne L. Holleran +10 more

Complete response to anti-PD-L1 antibody in a metastatic bladder cancer associated with novel MSH4 mutation and microsatellite instability

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2019-000128

N/A

0DataRank · unranked

60 citations

Rohit Jain, Sean T. Glenn, Bo Xu, Prashant K. Singh, Lei Wei +7 more

Germline whole-exome sequencing reveals FOXP3-related gene variants conferring urinary cancer susceptibility and associated with immune escape

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2024-010417

N/A

0DataRank · unranked

0 citations

Wendy Kohlmann, David A. Nix, Aaron Atkinson, Kenneth M. Boucher, Courtney Carroll +21 more